• <a fr-original-style="" href="https://www.ft.com/content/df20b1b7-6368-44bb-803d-b8602d575275" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Shares in Roche</a> dropped as much as 5.9% on Monday after the Swiss drugmaker announced that its long-awaited drug for Alzheimer’s disease failed in a pair of large studies. The experimental medicine, called gantenerumab, didn’t slow clinical decline in people with early Alzheimer’s at a statistically significant level.<img src="https://images.aposto.com/2022/10/1/1668453908326.png" style="display: block; float: none; vertical-align: top; margin: 5px auto; text-align: center; width: 100%; max-width: 550px; border-style: none; position: relative; cursor: pointer; padding: 0px 1px; box-sizing: border-box;" ratio="1.79" width="550" alt="Alzheimer’s treatment research" fr-original-style="display: block; float: none; vertical-align: top; margin: 5px auto; text-align: center; width: 100%; max-width: 550px;" fr-original-class="fr-draggable">via FT<ul fr-original-style="padding-inline-start: 20px;" style="padding-inline-start: 20px; margin-top: 0px; margin-bottom: 1em; list-style-position: inside; box-sizing: border-box;"><li fr-original-style="" style="box-sizing: border-box;">The competition: Lecanemab, a similar treatment by Biogen and Eisai, hit a milestone two months ago, becoming the first product to slow the progression of Alzheimer’s in a definitive trial.</li></ul>

Lecanemab ile ilgili hikayeler